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Abstract 
Background: When applying information gathered from medical research to the clinical setting, it is imperative that 
the sample of the investigated patients be representative of the clinical population. Because of this fact, it is necessary 
to closely examine the sample’s baseline characteristics in clinical trials.
Methods: We analysed baseline data of relevant trials investigating considerable proportions of patients with atrial 
fibrillation (AF) in the secondary stroke prevention: EAFT, SIFA, Active-W, BAFTA, RE-LY, AVERROES, ARISTOTLE and 
ROCKET AF. For comparing baseline data stroke patients with AF documented in a statutory stroke registry were con-
sidered. In a subgroup of patients (members of a large insurance) data on subsequent prescription for oral anticoagu-
lants (oAK) were available.
Results: In the stroke registry (n = 15,886) the mean age was higher than in the selected clinical trials (mean 77.7 
versus 70–72 years). Among insurance members (n = 1,828), those with a prescription for oAK (n = 827) were older 
than patients recruited in clinical trials (mean 75.1 versus 70–72 years). Results also showed that the male sex was 
overrepresented in clinical trials (59–63% versus 46%). The distribution of vascular risk factors in recent clinical trials 
was comparable to proportions in the registry (hypertension: 77–85% versus 80%; diabetes mellitus: 20–26% versus 
27%).
Conclusions: The majority of stroke patients with AF in the clinical setting are considerably older than those 
included in clinical trials. While the distribution of vascular risk factors in clinical trials corresponds to proportions 
observed in clinical practice, an overrepresentation of the male sex in clinical trials is evident.
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Background
Evidence-based medicine, identified in clinical trials, 
is crucial to facilitate appropriate decision-making in 
patient care. However, patients in clinical trials inevitably 
represent a selected sample of the population. As a result, 
physicians might challenge the external validity especially 
in specific subgroups such as elderly patients. Addition-
ally, different sources of bias might distort results. One of 
the most important and most often discussed confound-
ing variables is selection bias, which occurs when con-
sidering patients to participate in a study [1]. Applying 
information derived from medical research into the clini-
cal setting depends on the generalizability of the investi-
gated patients to the population of interest.
A large number of studies have shown the efficacy 
of oral anticoagulation (OA) in atrial fibrillation (AF) 
[2–10]. These studies evaluated primary and second-
ary stroke prevention with results demonstrating the 
substantial benefit of OA [2–10]. Therefore, it is crucial 
to determine how the baseline characteristics of study 
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samples compare to those of patients encountered in 
clinical practice and nation-wide populations.
In the presented investigation, we aimed to analyse 
baseline characteristics in relevant clinical trials of atrial 
fibrillation when compared to stroke victims documented 
in a larger, more representative stroke registry sample.
Methods
We evaluated the baseline data of previous clinical trials 
with substantial proportions of stroke patients with atrial 
fibrillation, including: EAFT, SIFA, Active-W, BAFTA, 
RE-LY, AVERROES, ARISTOTLE and ROCKET AF 
[2–10]. Characteristics such as age, sex, vascular risk fac-
tors including hypertension and diabetes mellitus were 
investigated. For RE-LY, ARISTOTLE and ROCKET AF 
baseline data and frequencies calculated in the stroke 
subgroups were collected for analysis.
For comparison, we gathered baseline data from 
ischaemic stroke or TIA patients with AF documented 
(2004–2010) in the stroke registry (n =  15,886) of the 
Institute of Quality Assurance Hesse (Geschäftsstelle 
für Qualitätssicherung, GQH) (Figure 1) [11]. Patients 
with a haemorrhagic stroke or intracranial bleeding 
were excluded from this study sample. Patients with 
moderate disability (modified Rankin scale ≤3 as 
assessed on discharge) were selected because these 
patients might most meet the criteria for measures in 
the secondary stroke prevention such as intake of oral 
anticoagulants. This selection might further provide 
certain structural equality regarding the disability sta-
tus when comparing patients in clinical trials versus 
daily practice.
Among this sample, we selected a subgroup of patients 
(n = 827) from a large health insurance consortium with 
evidence of a prescription for oral anticoagulants (oAK). 
For this subgroup insurance data between 2005 and 2007 
was used. In order to identify pertinent members of this 
insurance, we examined patients matching a set of crite-
ria including date of birth, date of hospital admission and 
the admitting hospital. This data was linked in a pseu-
donymous manner. For our analysis, we selected patients 
without further hospitalisation in a 30-day period within 
90 days after discharge (n = 1,828). We defined evidence 
of a prescription for oral anticoagulants (including phen-
procoumaron, warfarin and coumadin) as a marker of 
anticoagulation. This information was gathered from 
the insurance claims; 827 patients were identified. For 
the categorical variables, data was presented in propor-
tions. A Chi squared test was used to compare propor-
tions between the entire sample identified in the Hessian 
stroke registry, the EAFT and SIFA’s samples, and the 
subgroups of patients with a previous stroke or TIA in 
RE-LY, ARISTOTLE and ROCKET AF.
The protocol of the present study was reviewed and 
approved by the ethical committee of the medical faculty 
of the Justus Liebig University Giessen.
GQH
The GQH database is a mandatory nationwide hospital-
based registry spanning more than 95% of all ischaemic 
strokes, transient ischaemic attacks (TIA), and intracer-
ebral haemorrhages in more than 6 million residents of 
Hesse, Germany. The GQH includes data of acute inpa-
tient treatment, as well as factors proven to be relevant 
for the course and the prognosis of a stroke. For quality 
assurance purposes, the acquisition of this data is regu-
lated by law and implemented as a guideline, which is 
elaborated by the Federal Joint Committee for hospital 
quality assurance in accordance with Volume V of the 
Social Insurance Code (§137 SGB V and §135a SGB V). 
Based on this regulation, the Hesse State Hospital Law 
contains a provision that allows the GQH to record such 
data legally. The publication of aggregate quality assur-
ance data has been approved by the Hesse Data Protec-
tion Commissioner, so no data protection problem arises 
here [12–14].
151.158 cases of ischemic stroke or TIA, bleedings and other 
aetiologies documented in the hessian registry (2004-2010)  
18.154 bleedings or other 
aetiologies (e.g. CVT)
133.004 cases of ischemic 
stroke or TIA
28.971 documented cases of atrial fibrillation   
10.851 cases with documented 
mRs>3 on discharge
18.120 cases with documented 
mRs≤3 on discharge
15.886 with documented discharge at home (n=11.336) or to an 
department for rehabilitation (n=4.550) 
1828 patients without obvious contraindications for anticoagulants 
2101 patients affiliated to the insurance treated 2005 - 2007  
119 cases of recurrent stroke   
103 deceased within the 90 day follow-up 
51 cases without a 30 days interval at home or 
incomplete 90 days follow up
Figure 1 Patient selection within the stroke registry data set. TIA 
refers to transient ischaemic attack, CVT refers to cerebral vein throm-
bosis, mRs refers to modified Rankin scale.
Page 3 of 6Tanislav et al. BMC Res Notes  (2015) 8:262 
Results
In the GQH registry sample (n = 15,886) the mean age 
was 77.7  years. Apart from the BAFTA trial (mean age 
81.5 years), the mean age in the selected trials and sub-
groups of patients with a previous stroke or TIA ranged 
between 70 and 72 years. In the insurance subgroup the 
mean age was comparable to the registry sample (77.6 
versus 77.7 years) (Table 1). In the insurance subgroup of 
patients with a prescription for oAK, the mean age was 
75.1 years and in those without evidence of a prescription 
the mean age was 79.8.
The proportion of males in the registry sample was 
46%, while in the insurance subgroup only 41% of 
patients were male. The proportion of males increased 
in the insurance subgroup of patients with an oAK pre-
scription to 48.1%. Apart from SIFA (proportion of male 
patients 47%) there was a majority of males reaching 
55–66% in the selected clinical trials (Table 1).
The proportion of hypertension and diabetes mellitus 
in the registry population, in the selected trials, and in 
the subgroups of patients with a previous stroke or TIA 
were similar (hypertension 80, 79 and 79.8%); diabetes: 
27, 29 and 29%) (Table 1). Earlier investigations (EAFT, 
SIFA and BAFTA) focused on patients with a moder-
ate vascular burden and had lower proportions of these 
risk factors (hypertension: 44–55% of the patients; dia-
betes mellitus: 13–16% of the patients). In recent tri-
als (Active-W, RE-LY, AVERROES, ARISTOTLE and 
ROCKET AF) these factors are of similar proportions 
when compared to the registry population (hyperten-
sion: 77–86% of the patients; diabetes mellitus: 20–26% 
of the patients).
Using a Chi squared test, we compared the propor-
tions of these characteristics among the entire study sam-
ple, which was composed of the Hessian stroke registry 
and the EAFT and SIFA populations and the subgroups 
of patients with stroke or TIA in RE-LY, ARISTORLE 
and ROCKET AF. Results showed that in the majority 
of the cases p values were <0.001 (Table 1). However, no 
relevant differences were identified in the comparison 
between proportions of patients with diabetes mellitus 
in the registry study group and the stroke or TIA sub-
group in ARISTOTLE (27 versus 26%, P =  0.1317) and 
the gender comparison with SIFA (males: 46 versus 47%, 
P = 0.5889).
Discussion
In the registry population patients were on average 
7 years older than those included in the selected studies 
[2–10]. Apart from age, the comparison of baseline char-
acteristics revealed an overrepresentation of male indi-
viduals in clinical trials. The proportions of vascular risk 
factors such as hypertension and diabetes mellitus were 
comparable in recent clinical trials with those seen in 
clinical practice.
It is also important to note that factors such as age 
might impact a patient’s inclusion in clinical trials on OA. 
In these clinical trials, there are strict inclusion criteria 
that determine whether or not a patient is included. The 
factor age may bias the inclusion in studies due to the 
increased risk of bleeding in the elderly and as a result 
elderly patients may be less selected for inclusion in clini-
cal trials for OA. In our GQH registry sample the mean 
age within the subgroup of patients with prescriptions for 
oAK was lower than in the total registry sample (75.1 vs. 
77.7 years respectively); however, it still ranged above the 
mean age observed in clinical trials (75.1 vs. 70–72 years).
The BAFTA trial, which included oAK for individu-
als with AF over 75  years of age, reported a 2.4% abso-
lute risk reduction per year and a similar risk for major 
bleeding when compared to aspirin (1.9 versus 2.0%) 
[8]. While distributions of vascular risk factors in the 
recent trials are comparable to proportions calculated in 
the registry population, participants in the BAFTA-trial 
were less affected by vascular risk factors (hypertension: 
80 versus 54%; diabetes mellitus 27 versus 13%) [8]. The 
burden of leukoaraiosis, microbleeds and silent brain 
infarctions, which correlates with the presence of vascu-
lar risk factors, substantially increases beyond 75 years of 
age; this results in a higher risk for intracerebral haem-
orrhage [15–20]. In the BAFTA selection process there 
was a preference for elderly individuals without consid-
erable vascular burden. Therefore, those patients with 
supposedly higher risk for bleeding were less preferred 
for inclusion. Furthermore, regarding secondary stroke 
prevention, the BAFTA trial is of limited benefit, as only 
a small proportion of patients who have had a previous 
stroke were investigated (13%) [8].
ROCKET AF claims to address more elderly patients 
(median 73  years) [10]. However, in the subgroup of 
patients with a previous stroke, the median age decreases 
(median 71  years) corresponding with the subgroups 
in RE-LY (mean 70.5  years) and ARISTOTLE (mean 
70.1  years) [7]. In this case the additional burden of a 
previous cerebrovascular event a further bias to younger 
patients.
In many clinical trials males represent the majority 
of the participants [2–4, 21, 22]. In contrast, in nation-
wide data collections, males do not exceed 50% [23–25]. 
In line with this finding, the proportion of male partici-
pants in our nationwide registry was also lower than in 
clinical trials (46% versus 55–66%). This might also be a 
result of the increased age of the participants as females 
suffer from stroke later in life than males [18]. Consistent 
with this assumption, the slight decrease in age within 
the insurance subgroups (mean 77.6 versus 75.1  years) 
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corresponded with a higher proportion of male subjects 
(41.8–48.1%).
Even though EAFT and SIFA included a small number 
of patients with a relatively moderate burden of vascular 
risk factors, we considered these two ground-breaking 
trials, because both specifically addressed stroke patients 
in secondary prevention [2, 9]. In these trials the signifi-
cant advantage of oAK over a therapy with platelet inhib-
itors was demonstrated. In contrast, the vast majority of 
AF trials provided evidence for the safety and efficacy of 
OA in the general population of both stroke and non-
stroke patients. The percentage of stroke patients ranged 
from 13 to 25% in these trials. Despite methodological 
limitations, specifically the small number of patients, 
these subgroup analyses indicated the efficacy of OA in 
patients with AF after having a stroke [4, 5, 22]. Indisput-
ably, the participation of stroke patients in AF trials is 
crucial because they face higher risks of both recurrent 
stroke and bleeding complications [18]. Because of this 
higher risk of a worse outcome, it is difficult to extrapo-
late the benefit of OA in secondary prevention from pri-
mary prevention studies. Trials designed to specifically 
investigate patients within secondary stroke prevention 
would be ideal.
Conclusions
Despite clear evidence of the efficacy of OA, there is an 
age-dependent variable when considering stroke patients 
for this treatment. There is a considerable difference in 
age of patient populations in clinical trials when compared 
with clinical practice. Results have shown that in clinical 
trials younger patients (70–72 years) are preferable; how-
ever, in clinical practice, patients selected for OA are older 
(75.1  years) than those in trials, but also younger than 
those who are selected for alternative therapy (79.8 years). 
With regard to the vascular risk factors of hypertension 
and diabetes mellitus, we found that the proportions in 
recent clinical trials are comparable to those in clinical 
practice. Both patients and clinicians would benefit from 
further investigations into secondary stroke prevention 
when selecting patients suitable for OA. Currently evi-
dence is generally collected from studied in the primary 
stroke prevention with considerably younger patients.
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